Study of Efficacy and Safety of Tisagenlecleucel in High Risk (HR) B-cell Acute Lymphoblastic Leukemia (ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy (CASSIOIPEIA)

This is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in de novo HR pediatric and young adult B-ALL patients who received first-line treatment and are EOC MRD positive. The study will have the following sequential phases: screening, pre-treatment, treatment & follow-up, and survival. After tisagenlecleucel infusion, efficacy will be assessed at Day 29, then every 3 months for the first year, every 6 months for the second year, then yearly until the end of the study. Safety will be assessed throughout the study. The study is expected to end in approximately 8 years after first patient first treatment (FPFT). A post-study long term follow-up for lentiviral vector safety will continue under a separate protocol per health authority guidelines. (AALL1721/ CCTL019G2201J)